EVALUATING CURRENT ATTITUDES REGARDING PARENTAL GENETIC TESTING FOR BETA THALASSEMIA AMONG PREGNANT WOMEN IN PAKISTAN
DOI:
https://doi.org/10.71000/nrq0rd49Keywords:
Pregnant Women, Genetic Disorder, Prenatal testing, Genetic Counselling, Thalassaemia, Hemoglobin, Anxiety and DepressionAbstract
Background: Thalassemia is one of the most common inherited hemoglobinopathies, resulting from reduced or absent synthesis of alpha (α) or beta (β) globin chains. In countries like Pakistan, where consanguineous marriages are common, the risk of transmitting such genetic disorders increases. Prenatal genetic testing, particularly chorionic villus sampling (CVS), offers early diagnosis but may contribute to maternal psychological distress, which remains underexplored in local populations.
Objective: To assess the knowledge, attitudes, and psychological responses of pregnant Pakistani women undergoing CVS for thalassemia screening.
Methods: This cross-sectional study was conducted between April and June 2024 at the Thalassemia Department of Bahawalpur Victoria Hospital, Punjab, Pakistan. A total of 48 pregnant women, between 11–14 weeks of gestation and confirmed thalassemia carriers, were enrolled. Data were collected using a structured, interviewer-administered questionnaire covering demographic details, clinical history, knowledge of thalassemia, attitudes toward CVS, and psychological experiences. Descriptive statistics were used to summarize responses, and ordinal logistic regression was performed to explore associations between gestational age, emotional responses, and willingness to undergo testing.
Results: Among the 48 participants, 54.2% expressed willingness to undergo CVS again in future pregnancies. A majority (72.9%) reported favorable attitudes toward genetic testing. About 60.4% cited active partner support during the diagnostic process. Women with previously affected children showed greater acceptance of CVS. Sleep disturbances and anxiety were more pronounced in early gestation, while overall psychological strain remained minimal due to familial and clinical support systems.
Conclusion: Prenatal CVS testing was generally well-tolerated among thalassemia-carrier pregnant women. Support from partners, family, and healthcare providers played a pivotal role in alleviating maternal anxiety and enabling informed decision-making.
References
Yousuf, R., Akter, S., Wasek, S. M., Sinha, S., Ahmad, R., Haque, M., & Salam, M. W. (2022). Thalassemia: A Review of the Challenges to the Families and Caregivers. Cureus, 14(12).
Khaliq, S. (2022). Thalassemia in Pakistan. Hemoglobin, 46(1), 12-14.
Babker, A. M. (2022). An overview on thalassemia and challenges during COVID-19. International Journal of Health Sciences, (I), 3207-3220.
Tesio, N., & Bauer, D. E. (2023). Molecular basis and genetic modifiers of thalassemia. Hematology/oncology clinics of North America, 37(2), 273-299.
M. M., Molina, F. S., Rodríguez-Fernández, M., Delgado, J. L., Carrillo, M. P., Jani, J., Plasencia, W., Stratieva, V., Maíz, N., Carretero, P., Lismonde, A., Chaveeva, P., Burgos, J., Santacruz, B., Zamora, J., & De PacoMatallana, C. (2020). New approach for estimating risk of miscarriage after chorionic villus sampling. Ultrasound in obstetrics &gynecology: the official journal of the International Society of Ultrasound in Obstetrics and Gynecology, 56(5), 656–663.
Likar, I. P., Jere, K. S., Možina, T., Verdenik, I., & Tul, N. (2020). Pregnancy Loss After Amniocentesis and Chorionic Villus Sampling: Cohort Study. Zdravstveno varstvo, 60(1), 25–29.
Hekmat, K., Kamali, F., Abedi, P., & Afshari, P. (2023). Explaining mothers’ experiences of performing fetal health screening tests in the first trimester of pregnancy: A qualitative study with content analysis approach. International Journal of Africa Nursing Sciences, 18, 100565.
Gibson, L., Ikhile, D., Nyashanu, M., & Musoke, D. (2023). Health promotion research in international settings: A shared ownership approach for north-south partnerships. In Global Handbook of Health Promotion Research, Vol. 3: Doing Health Promotion Research (pp. 263-272). Cham: Springer International Publishing.
Garcia, E., Henneman, L., Gitsels-van der Wal, J. T., Martin, L., Koopmanschap, I., Bekker, M. N., & Timmermans, D. R. (2022). Non-invasive prenatal testing (NIPT) and pregnant women’s views on good motherhood: a qualitative study. European Journal of Human Genetics, 30(6), 669-675.
Mojahed, S., Tabatabaei, R. S., Reihani, F., Dehghani, A., & Khavari, F. (2021). The effect of education on anxiety of pregnant mothers before amniocentesis. Journal of education and health promotion, 10(1), 61.
Sheikh, Z. A., & Wahlberg, A. (2023). More than sample providers: how genetic researchers in Pakistan mobilized a prenatal diagnostic service for thalassemia. BioSocieties, 18(1), 197-217.
Bedei, I., Wolter, A., Weber, A., Signore, F., & Axt-Fliedner, R. (2021). Chances and challenges of new genetic screening technologies (NIPT) in prenatal medicine from a clinical perspective: a narrative review. Genes, 12(4), 501.
Di Mattei, V., Ferrari, F., Perego, G., Tobia, V., Mauro, F., & Candiani, M. (2021). Decision-making factors in prenatal testing: A systematic review. Health psychology open, 8(1), 2055102920987455.
Mensah, C., & Sheth, S. (2021). Optimal strategies for carrier screening and prenatal diagnosis of α-and β-thalassemia. Hematology, 2021(1), 607-613.
Ngan, O. M. Y., Yi, H., Bryant, L., Sahota, D. S., Chan, O. Y. M., & Ahmed, S. (2020). Parental expectations of raising a child with disability in decision-making for prenatal testing and termination of pregnancy: A mixed methods study. Patient Education and Counseling, 103(11), 2373-2383.
Farrell RM, Pierce M, Collart C, Yao M, Coleridge M, Chien EK, et al. Decision-making for prenatal genetic screening: how will pregnant women navigate a growing number of aneuploidy and carrier screening options? BMC Pregnancy Childbirth. 2021;21(1):806.
Farrell, R. M., Pierce, M., Collart, C., Yao, M., Coleridge, M., Chien, E. K., ... & Edmonds, B. T. (2021). Decision-making for prenatal genetic screening: how will pregnant women navigate a growing number of aneuploidy and carrier screening options. BMC Pregnancy and Childbirth, 21, 1-10.
Liu D, Nong X, Lai F, Nong C, Wang T, Tang Y. Noninvasive Prenatal Diagnosis of SEA-Thalassemia by Combining 1000 Genomes Database and Relative Haplotype Dosage. Hemoglobin. 2024;48(2):71-8.
Charoenkwan P, Traisrisilp K, Sirichotiyakul S, Phusua A, Sanguansermsri T, Tongsong T. Noninvasive Prenatal Diagnosis of Beta-Thalassemia Disease by Using Digital PCR Analysis of Cell-Free Fetal DNA in Maternal Plasma. Fetal Diagn Ther. 2022;49(11-12):468-78.
Erlich HA, Ko L, Lee J, Eaton K, Calloway CD, Lal A, et al. Non-invasive prenatal testing of beta-hemoglobinopathies using next generation sequencing, in-silico sequence size selection, and haplotyping. Croat Med J. 2024;65(3):180-8.
Madgett TE. First Trimester Noninvasive Prenatal Diagnosis of Maternally Inherited Beta-Thalassemia Mutations. Clin Chem. 2022;68(8):1002-4.
Jiang H, Zhou C, Yang L, Li S, Liu X. [Carrier screening and prenatal diagnosis for thalassemia-associated mutations in Jiaxing area of Zhejiang]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2023;40(3):295-300.
Wu J, Xie D, Wang L, Kuang Y, Luo S, Ren L, et al. Application of third-generation sequencing for genetic testing of thalassemia in Guizhou Province, Southwest China. Hematology. 2022;27(1):1305-11.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Iqra javaid, Abdul Mannan, Sabiha Khalid, Aroosa Farooq, Muhammad Danish, Rabia Basri, Muhammad Akram, Maheen Farooqi (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
